Indian-based drug company BDR Pharmaceuticals has announced the launch of generic cabozantinib for the treatment of metastatic medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma, according to The Economic Times.
BDR Pharmaceuticals focuses on developing therapeutic segments in oncology, critical care, gynecology, and neurology.
Sold under the brand names Cometriq and Cabometyx, cabozantinib is a chemotherapy drug that belongs to a class of drugs called receptor tyrosine kinase inhibitors. It is used for the treatment of metastatic medullary thyroid cancer, advanced renal (kidney) cell carcinoma, and hepatocellular (liver) cancer.
The drug blocks the signals inside cancer cells that make them grow and proliferate.
In several trials, the drug has shown better progression-free survival.
Raheel Shah, Director Of Business Development at BDR, said, “World-class treatment at a reasonable rate was the main reason for launching the drug in India.”
“Though we have been outstretched in all departments to deliver on COVID treatment on an emergency basis, we have not allowed this to hamper our efforts on other equally important priority segments, including oncology,” he added. “The result is the advent of the development of this new generic cancer molecule called cabozantinib [Cabozinab].”
The Drugs Controller General of India (DGCI) has also approved BDR’s cabozantinib to be put into medicinal use. The company said it will soon make generic cabozantinib available in India.
